Helixate® FS is a recombinant factor VIII (FVIII) product used to treat hemophilia A when there is a demonstrated deficiency of FVIII, a plasma clotting factor.
Helixate® FS should be administered cautiously in patients with previous hypersensitivity to constituents of FVIII preparations of known sensitivity to mouse or hamster protein.
Adverse events are generally minor. The most common adverse events include injection-site reactions, dizziness, and rash.
